Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impair...(ts underwent genomic testing for variati...),Health

Date:8/29/2007

ts underwent genomic testing for variations in the coding regions of genes known to influence memory and cognition, including the apolipoprotein E gene (APOE), a known genetic risk factor for Alzheimer's disease (AD) that occurs in 15-20% of the general population. On days 0, 30, 60, 90 and 104, subjects were evaluated through a battery of neuropsychometric tests that measure various aspects of memory and cognition.

Ketasyn showed significant efficacy in tests of memory. On average, subjects taking Ketasyn performed significantly better on the 'First-Last Name Association' test (FLN) than subjects taking placebo (p=0.042). "On average, seniors taking Ketasyn remembered more names than those taking placebo," said Dr. Costantini.

In another memory test called Name-Face Recognition (NFA), which associates a person's name and face, Ketasyn subjects under age 59 improved significantly more than placebo subjects at Day 90 (p=0.0217). The efficacy in the NFA test observed with Ketasyn in subjects under age 59 captures a large portion of the AAMI population.

Consistent with the findings of Accera's Phase IIa and IIb AD studies, subjects who did not have the APOE4 genotype (E4(-)) responded particularly well to treatment: E4(-) subjects showed a further significant treatment effect of Ketasyn in FLN at Day 90 (p=0.012). In contrast, and also consistent with the AD trial results, APOE4(+) subjects showed no difference between Ketasyn and placebo for FLN scores at Day 90 (p=0.4639).

The safety profile of Ketasyn was excellent, as shown in the previous AD trials with Ketasyn. The incidence of adverse events was low and similar between Ketasyn and placebo groups.

Accera recently completed a Phase IIb clinical trial in AD patients that confirmed Ketasyn's safety and efficacy as measured by improvement in ADAS-Cog scores, the gold standard measure for efficacy in cognition and short-term memory. Accera plans to initiate a pivotal, Phase III multi-cent
'/>"/>

SOURCE Accera, Inc. Copyright©2007 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3
Related medicine technology :

1. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
2. Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus
3. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
4. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
5. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
10. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
11. First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A) Significantly Improves Idiopathic Detrusor Overactivity (IDO) in Patients With Symptoms of Overactive Bladder